Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNP004
- Development stage
- Preclinical
- Lead developer
- KumhoHT
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
DNP004 is a preclinical-stage humanized monoclonal antibody targeting carbonic anhydrase XII (CA12 or CA XII). Originally developed by Dinona, the asset's development and commercialization rights were licensed to Aprogen (formerly Aprogen KIC / Aprogen Medicine) in 2018. Following Dinona's merger into KumhoHT in 2021, KumhoHT became the successor developer alongside Aprogen. DNP004 is designed to bind to CA12, an enzyme overexpressed in various solid tumors, particularly triple-negative breast cancer (TNBC). By targeting CA12, DNP004 aims to inhibit tumor growth and induce antibody-dependent cellular cytotoxicity (ADCC) in CA12-expressing cancer cells. Preclinical studies in animal models have demonstrated its efficacy in reducing tumor volume.
02
Targets
CA12 (Carbonic anhydrase XII)
Beyond the preview
Go deeper on DNP004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNP004.